Signal · Supply Chain & Logistics
Hanmi signs record $2.3b obesity drug deal with Genentech
What the source reported
Source-reportedHanmi Pharmaceutical said Monday it has inked an exclusive licensing agreement with Genentech for its obesity drug candidate HM17321 in a deal that could be worth up to $2.3 billion, setting new record for the firm for a licensing contract of a single drug candidate. Under the contract, Hanmi will receive an upfront payment of $190 million from Genentech, a US biotechnology subsidiary of Swiss multinational pharmaceutical giant Roche. The total value of the deal could reach as much as $2.3 billi
- Publication
- The Korea Herald - Business · Business News
- Published
- 24th August 2026
- Original report
- koreaherald.com
ProcIntel stores what the source published in its feed — a headline, a summary and a link. It does not store or reproduce the full article.
What ProcIntel recorded
ProcIntel-derived- Category
- Supply Chain & Logistics
- Geography
- South Korea
- Organisations
- None identified
- Collected
- 24th August 2026 · 06:28
Initial assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Initial Significance Low (18.0/100). Strongest contributor: Procurement Impact (6.0/30 points). Limiting factor: Likely Event Severity (3.0/30 points). Initial Confidence Very Low (18.5/100, data sufficiency: Partial). Strongest contributor: Source Authority (12.0/40 points). Limiting factor: Corroboration (2.5/25 points).
- Strongest contributor
- Procurement Impact
- Limiting factor
- Likely Event Severity